A Randomized, Double-blind, Multi-center, Phase Ⅳ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety Between Amlodipine Besylate/Candesartan Cilexetil Combination Tablets and Co-administration of Amlodipine Besylate and Candesartan Cilexetil in Patients With Essential Hypertension
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Amlodipine/candesartan-cilexetil (Primary) ; Amlodipine; Candesartan cilexetil
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms MACH
- Sponsors CJ HealthCare
- 15 Oct 2018 Planned End Date changed from 31 Dec 2018 to 31 May 2019.
- 15 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 30 Apr 2019.
- 02 Aug 2017 New trial record